Breast Cancer

William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of Medicine (Hematology and Oncology), Northwestern University Feinberg School of Medicine, discusses selecting agents for the treatment of patients with HER2-positive breast cancer.

Lisa Carey, MD, discusses the challenges with de-escalation in patients with TNBC and steps toward overcoming these obstacles.

Gunter von Minckwitz, MD, PhD, discusses the APHINITY results and their implication for the use of pertuzumab in patients with HER2-positive breast cancer.

Twelve weeks of neoadjuvant T-DM1 with or without endocrine therapy induced superior pathologic complete response compared with trastuzumab (Herceptin) plus endocrine therapy in patients with HER2-positive/HR-positive early breast cancer.

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses pertuzumab (Perjeta) plus trastuzumab (Herceptin) and chemotherapy for patients with HER2-positive breast cancer.

Arti Hurria, MD, discusses the unique challenges with treating elderly patients with breast cancer and the exciting opportunities she envisions for advancing care in this setting.

Henry M. Kuerer, MD, PhD, professor of surgery, The University of Texas MD Anderson Cancer Center, discusses margins of ductal carcinoma in situ (DCIS).

Mark Pegram, MD, discusses emerging treatments in HER2-positive breast cancer and his vision for the future of the field.

The introduction of targeted therapies has transformed HER2-positive breast cancer from an aggressive disease with poor outcomes to a highly manageable disease with potential for long-term survival.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neoadjuvant HER2-directed therapy.

While several biomarkers have been identified in patients with breast cancer, including ESR1 and PIK3CA mutations, not all of these are driver mutations that can be effectively targeted with treatment.

Experts are trying to determine whether combination regimens with additional HER2-directed therapies or alternative therapies could improve responses in HER2-positive breast cancer without added toxicities.

The European Commission has approved the use of fulvestrant (Faslodex) to treat estrogen receptor-positive, locally-advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.

Checkpoint inhibitors against PD-1 and PD-L1 have shown promise, both as monotherapies and in combination with chemotherapy for patients with triple-negative breast cancer.

Joyce O'Shaughnessy, MD, provides an update on existing research and a look at the future of novel therapeutic strategies for metastatic triple-negative breast cancer.

The FDA has approved neratinib (Nerlynx) for the extended adjuvant treatment of patients with early stage, HER2-positive breast cancer following postoperative trastuzumab.

Arti Hurria, MD, director, Cancer and Aging Research Program, co-leader, Cancer Control and Population Sciences Program, professor, Department of Medical Oncology and Therapeutics Research and Department of Population Sciences, discusses treatment for the geriatric patient population with breast cancer.

Hope S. Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses extended adjuvant hormone therapy for patients with breast cancer.

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses the 5 versus 10 year disease-free survival of aromatase inhibitors investigated in the NSAPB B-42 trial.

The FDA’s Oncologic Drugs Advisory Committee voted 16-0 to recommend approval to MYL-1401O, the trastuzumab (Herceptin) biosimilar manufactured by Mylan Pharmaceuticals.

Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.

The FDA has granted a priority review to a new drug application for the CDK4/6 inhibitor abemaciclib as a treatment for patients with advanced hormone receptor–positive, HER2-negative breast cancer.

The triplet combination of HER2-targeted therapy and an aromatase inhibitor improved progression-free survival by more than 5 months compared with the combination of trastuzumab (Herceptin) and an aromatase inhibitor in patients with HER2+/HR+ breast cancer.

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the results of the APT and APHINITY trials for patients with HER2-positive breast cancer.